293 related articles for article (PubMed ID: 15620822)
21. Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain.
Ramos JM; Clavijo A; Moral L; Gavilan C; Salvador T; González de Dios J
Paediatr Int Child Health; 2018 Aug; 38(3):203-208. PubMed ID: 29790825
[TBL] [Abstract][Full Text] [Related]
22. Acute phase proteins and plasma lipoproteins during antimony treatment in infantile visceral leishmaniasis.
Kallel R; Bekaert ED; Dubois DY; Alcindor LG; Ayrault-Jarrier M; Mebazza A
Clin Physiol Biochem; 1993; 10(1):8-12. PubMed ID: 8339522
[TBL] [Abstract][Full Text] [Related]
23. [Chronic visceral leishmaniasis during chemotherapy for metastatic osteosarcoma].
Marguglio A; Hoyoux C; Dresse MF; Chantraine JM; Thiry A; Gillet P
Arch Pediatr; 1998 Mar; 5(3):285-8. PubMed ID: 10327996
[TBL] [Abstract][Full Text] [Related]
24. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.
Solomon M; Pavlotsky F; Leshem E; Ephros M; Trau H; Schwartz E
J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):973-7. PubMed ID: 21129042
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in the treatment of visceral leishmaniasis.
Davidson RN; Croft SL
Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221
[No Abstract] [Full Text] [Related]
26. Visceral leishmaniasis and disseminated intravascular coagulation in a dog.
Font A; Gines C; Closa JM; Mascort J
J Am Vet Med Assoc; 1994 Apr; 204(7):1043-4. PubMed ID: 8045804
[TBL] [Abstract][Full Text] [Related]
27. [Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B].
Pérez Brea A; Ruiz Moreno M; Leal Orozco A; Escorihuela Esteban R; Otero Fraguas M
An Esp Pediatr; 1996 Feb; 44(2):161-3. PubMed ID: 8830578
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
29. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis.
Motta JO; Sampaio RN
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):331-5. PubMed ID: 21492255
[TBL] [Abstract][Full Text] [Related]
30. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
31. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
Berhe N; Ali A; Hailu A; Yeneneh H
Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358
[TBL] [Abstract][Full Text] [Related]
32. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy.
Cascio A; Gradoni L; Scarlata F; Gramiccia M; Giordano S; Russo R; Scalone A; Camma C; Titone L
Am J Trop Med Hyg; 1997 Jul; 57(1):75-8. PubMed ID: 9242323
[TBL] [Abstract][Full Text] [Related]
33. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
Valencia ME; Laguna F; González Lahoz J
An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
[No Abstract] [Full Text] [Related]
34. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
Oliveira-Neto MP; Schubach A; Mattos M; Gonçalves-Costa SC; Pirmez C
Pathol Biol (Paris); 1997 Jun; 45(6):496-9. PubMed ID: 9309267
[TBL] [Abstract][Full Text] [Related]
35. [Three Pediatric Cases of Leishmaniasis with Different Clinical Forms and Treatment Regimens].
Aydın Teke T; Metin Timur Ö; Gayretli Aydın ZG; Öz N; Bayhan Gİ; Yılmaz N; Mungan M; Tanır G
Turkiye Parazitol Derg; 2015 Jun; 39(2):147-50. PubMed ID: 26081889
[TBL] [Abstract][Full Text] [Related]
36. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds.
Lazanas MC; Tsekes GA; Papandreou S; Harhalakis N; Scandali A; Nikiforakis E; Saroglou G
AIDS; 1993 Jul; 7(7):1018-9. PubMed ID: 8357549
[No Abstract] [Full Text] [Related]
37. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Berman JD
Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
[No Abstract] [Full Text] [Related]
38. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion.
Berman J; Dietze R
Chemotherapy; 1999 Jun; 45 Suppl 1():54-66. PubMed ID: 10394022
[TBL] [Abstract][Full Text] [Related]
39. [Meeting "Visceral leishmaniasis in Maghreb", 2-4 April 2015 in Tunis. Recommendations].
Aoun K; Laamrani El Idrissi A; Harrat Z; Marty P
Bull Soc Pathol Exot; 2015 Aug; 108(3):229-30. PubMed ID: 26002086
[No Abstract] [Full Text] [Related]
40. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
